Nasdaq GlobeNewswire

ERYTECH to Host Second Quarter 2018 Conference Call and Business Update

Del

LYON, France, Sept. 06, 2018 (GLOBE NEWSWIRE) -- ERYTECH Pharma (Euronext Paris: ERYP - Nasdaq: ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating therapeutic drug substances inside red blood cells, today announced that it will host a second quarter 2018 conference call and webcast on Tuesday, September 11, 2018, at 2:30 PM CEST/8:30 AM EST to discuss operational highlights.

The call is accessible via the below teleconferencing numbers, followed by the Conference ID#: 4983808 #:

USA/Canada: +1 (833) 818-6807     France: +33 176748988
International Dial-In Number: +1 (409) 350-3501     United-Kingdom: +44 2031070289

The webcast can be followed live online via the link: https://edge.media-server.com/m6/p/z452iwaf

An archived replay of the call will be available for 7 days by dialing + 1 800 585 8367, Conference ID: 4983808 #. An archive of the webcast will be available on ERYTECH’s website, under the “Investors” section at http://investors.erytech.com.

About ERYTECH: www.erytech.com

Founded in Lyon, France in 2004, ERYTECH is a clinical-stage biopharmaceutical company developing innovative therapies for rare forms of cancer and orphan diseases. Leveraging its proprietary ERYCAPS platform, which uses a novel technology to encapsulate therapeutic drug substances inside red blood cells, ERYTECH has developed a pipeline of product candidates targeting markets with high unmet medical needs. ERYTECH’s initial focus is on the development of products that target the altered amino acid metabolism of cancer cells, depriving them of nutrients necessary for their survival.

The Company’s lead product, eryaspase, also known under the trade name GRASPA®, consists of an enzyme, L-asparaginase, encapsulated inside donor-derived red blood cells. L-asparaginase depletes asparagine, a naturally occurring amino acid essential for the survival and proliferation of cancer cells. L-asparaginase has been a standard component of multi-agent chemotherapy for the treatment of pediatric acute lymphoblastic leukemia (ALL), but side effects limit treatment compliance, especially in adults and patients with weak performance status.

Eryaspase demonstrated promising efficacy and safety results in various clinical trials in ALL, as well as in a Phase 2b trial in second-line pancreatic cancer. ERYTECH is preparing for the launch of a pivotal Phase 3 clinical trial in second line pancreatic cancer and Phase 2 trials in first line pancreatic cancer and triple-negative breast cancer.

ERYTECH produces eryaspase at its own GMP-approved and operational manufacturing site in Lyon (France), and at a site for clinical production in Philadelphia (USA). A large-scale manufacturing facility is under construction in New Jersey (USA).

In addition to eryaspase, ERYTECH is developing erymethionase, methionine-γ-lyase encapsulated in red blood cells, to target cancer cells’ amino acid metabolism and induce tumor cell starvation. ERYTECH is also exploring the use of its ERYCAPS platform for developing cancer immunotherapies (ERYMMUNE) and enzyme replacement therapies (ERYZYME).

ERYTECH is listed on the Nasdaq Global Select Market in the United States (ticker: ERYP) and on the Euronext regulated market in Paris (ISIN code: FR0011471135, ticker: ERYP). ERYTECH is part of the CAC Healthcare, CAC Pharma & Bio, CAC Mid & Small, CAC All Tradable, EnterNext PEA-PME 150 and Next Biotech indexes.

CONTACTS 

ERYTECH    
Naomi Eichenbaum
Director Investor Relations
NewCap
Mathilde Bohin/Louis-Victor Delouvrier
Investor relations
Nicolas Merigeau
Media relations
+33 4 78 74 44 38
+1 917 312 5151
naomi.eichenbaum@erytech.com
+33 1 44 71 94 94
ERYTECH@newcap.eu

Om Nasdaq GlobeNewswire

Nasdaq GlobeNewswire
Nasdaq GlobeNewswire
One Liberty Plaza - 165 Broadway
NY 10006 New York

+1 212 401 8700http://www.nasdaqomx.com

NASDAQ (NASDAQ: NDAQ) is a leading provider of trading, exchange technology, information and public company services across six continents.

Følg saker fra Nasdaq GlobeNewswire

Registrer deg med din epostadresse under for å få de nyeste sakene fra Nasdaq GlobeNewswire på epost fortløpende. Du kan melde deg av når som helst.

Siste saker fra Nasdaq GlobeNewswire

XBiotech Announces Granting of European Patent for Treatment of Inflammatory Skin Diseases26.9.2018 14:00Pressemelding

Broad European Patent Issued Supports XBiotech’s Skin Disease Program for Monoclonal Antibody Bermekimab AUSTIN, Texas, Sept. 26, 2018 (GLOBE NEWSWIRE) -- XBiotech Inc. (NASDAQ: XBIT) announced today that the European Patent Office has granted XBiotech a patent (Patent Number EP2694107) that covers the use of bermekimab as a treatment for inflammatory skin diseases. The patent includes data from studies showing that antibodies which specifically neutralize the activity of interleukin-1alpha (IL-1α) can reduce skin inflammation and treat inflammatory skin diseases. XBiotech has conducted a number of clinical trials in dermatology using bermekimab (an anti- IL-1α antibody), including ongoing studies in hidradenitis suppurativa and atopic dermatitis. XBiotech has also published clinical findings for the use of bermekimab for treatment of psoriasis and acne. The development of bermekimab for the treatment of inflammatory skin disorders is an important part of XBiotech’s commercialization p

CrownBio Completes Validation of Prostate Cancer Patient-Derived Xenograft (PDX) Models26.9.2018 14:00Pressemelding

Unique well-characterized prostate models derived from castration resistant and hormone sensitive primary tissue now available for studies SAN DIEGO, Sept. 26, 2018 (GLOBE NEWSWIRE) -- Crown Bioscience, a global drug discovery and development services company providing translational platforms to advance oncology, inflammation, cardiovascular and metabolic disease research, has announced the addition of unique, well characterized, fully annotated patient-derived xenograft (PDX) models of prostate cancer. Prostate cancer is the second most common cancer in males, impacting more than 1 million new patients worldwide each year. The disease has long been underrepresented at the preclinical modeling stage of drug development, due to the difficulty in establishing PDX models. CrownBio is committed to providing clinically relevant solutions for diseases with high unmet need. PDX are the most translatable preclinical models currently available, directly derived from patient tissue and reflectin

OTP Bank Selects eGain’s Knowledge Management for Customer Service26.9.2018 12:30Pressemelding

eGain’s AI and knowledge management solution will be deployed at the bank’s contact centres and retail branches with the support of eGain partner Pattern Digital Consulting SUNNYVALE, Calif. and NEWBURY, United Kingdom, Sept. 26, 2018 (GLOBE NEWSWIRE) -- eGain (NASDAQ: EGAN), the leading provider of cloud-based customer engagement solutions today announced that OTP Bank, one of the largest banks serving Central and Eastern Europe, has selected eGain for omnichannel customer service. Pattern Digital Consulting Ltd., an implementation partner for eGain, will work with eGain Quick Value Services™ team to deploy eGain’s award-winning solution for AI-infused knowledge to provide conversational, procedural, and process guidance to agents at the bank’s contact centers and retail branches. The bank tried out eGain’s solution as part of eGain Try+Buy™ consumption model, which is a risk-free production pilot with no obligation to buy and no-charge guidance for success. Happy with the agent exper

Canadian Natural Resources Limited Announces Completion of the Extension Period to Acquire All Issued and Outstanding Shares of Laricina Energy Ltd.26.9.2018 11:00Pressemelding

CALGARY, Alberta, Sept. 26, 2018 (GLOBE NEWSWIRE) -- Canadian Natural Resources Limited (“Canadian Natural" or the "Company") announces that Canadian Natural's offer to acquire all of the issued and outstanding common shares (the “Laricina Shares") of Laricina Energy Ltd. (“Laricina”) for $0.0815 per Laricina Share by way of a take-over bid (the "Offer"), as extended on September 13, 2018 for the mandatory 10-day extension period, expired at 11:59 p.m. (Mountain Daylight Time) on September 24, 2018. Since Canadian Natural's initial take up of 568,724,430 Laricina Shares on September 13, 2018, Computershare Investor Services Inc., the depositary, has reported that as at 11:59 p.m. (Mountain Daylight Time) on September 24, 2018, an additional 3,594,872 Laricina Shares (the "Additional Shares") were validly deposited under the Offer and not withdrawn. Canadian Natural has taken up and accepted for payment all such Additional Shares and payment for such Additional Shares will be made as so

Juniper Systems Unveils New Cedar CP3 Rugged Smartphone26.9.2018 06:36Pressemelding

BIRMINGHAM, United Kingdom, Sept. 25, 2018 (GLOBE NEWSWIRE) -- Juniper Systems Limited today announced the release of its newest Cedar™ device, the Cedar CP3™ Rugged Smartphone. The rugged smartphone arrives two years after its predecessor, the CT5™ Rugged Smartphone, bringing massive upgrades to nearly every specification. The CP3 touts battery life of 14-16 hours operating at full brightness and while running GPS. The CP3 is powered by a Snapdragon 653 octa-core processor, delivering fast load times and top-tier performance for advanced tasks without draining the battery. ‘Rugged doesn’t have to mean bulky and slow’, said Simon Bowe, general manager of Juniper Systems Limited. ‘The CP3 proves that smartphones can be purpose-built for data collection in the world’s toughest environments – and are also handy for surfing online at home’. The Cedar CP3 Rugged Smartphone is available globally and works on any GSM network. The powerful battery delivers a shocking 480-hour standby time and

Tenaris to acquire significant stake in Saudi Steel Pipe Company25.9.2018 22:58Pressemelding

LUXEMBOURG, Sept. 25, 2018 (GLOBE NEWSWIRE) -- Tenaris S.A. (NYSE, Buenos Aires and Mexico: TS and MTA Italy: TEN) announced today that it has entered into a definitive agreement to acquire from a private group 47.79% of the shares of Saudi Steel Pipe Company (“SSP”), a welded steel pipes producer listed on the Saudi stock market, for an aggregate price of US$144 million. The transaction is subject to regulatory approvals, including approval by the Capital Market Authority of Saudi Arabia, and other customary conditions and is expected to close in the first quarter of 2019. Tenaris has been serving Saudi Arabia’s oil and gas industry and Saudi Aramco for decades. With this transaction, Tenaris will significantly expand its industrial presence in the Kingdom and the range of products it supplies to Saudi Aramco. Since its first industrial investment in 2010, Tenaris has continuously invested to expand its local operations, supporting the industrialization of the country. SSP’s facilitie

I vårt presserom finner du alle våre siste saker, kontaktpersoner, bilder, dokumenter og annen relevant informasjon om oss.

Besøk vårt presserom